• Revenue Cycle Management
  • COVID-19
  • Reimbursement
  • Diabetes Awareness Month
  • Risk Management
  • Patient Retention
  • Staffing
  • Medical Economics® 100th Anniversary
  • Coding and documentation
  • Business of Endocrinology
  • Telehealth
  • Physicians Financial News
  • Cybersecurity
  • Cardiovascular Clinical Consult
  • Locum Tenens, brought to you by LocumLife®
  • Weight Management
  • Business of Women's Health
  • Practice Efficiency
  • Finance and Wealth
  • EHRs
  • Remote Patient Monitoring
  • Sponsored Webinars
  • Medical Technology
  • Billing and collections
  • Acute Pain Management
  • Exclusive Content
  • Value-based Care
  • Business of Pediatrics
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Practice Growth
  • Concierge Medicine
  • Business of Cardiology
  • Implementing the Topcon Ocular Telehealth Platform
  • Malpractice
  • Influenza
  • Sexual Health
  • Chronic Conditions
  • Technology
  • Legal and Policy
  • Money
  • Opinion
  • Vaccines
  • Practice Management
  • Patient Relations
  • Careers

Novavax COVID-19 vaccine gets emergency use authorization to be booster


FDA, CDC grant approve use for adults at least six months after first two-dose series, but with no booster.

Novavax COVID-19 vaccine gets emergency use authorization to be booster

Federal health authorities have granted emergency use authorization for the Novavax COVID-19 vaccine to be used as a booster shot for adults.

The U.S. Food and Drug Administration and the U.S. Centers for Disease Control announced the rulings Oct. 19. Pharmaceutical maker Novavax also announced the approvals for its COVID-19 vaccine, adjuvanted (NVX-CoV2373).

The shot now has emergency use authorization for use as a first booster in adults aged 18 years and older; as a two-dose primary series in adults aged 18 years and older; and as a two-dose primary series in adolescents aged 12 through 17 years, according to Novavax.

The federal actions give adults age 18 years and older an option to receive the Novavax COVID-19 vaccine, adjuvanted, as a booster instead of an updated (bivalent) Pfizer-BioNTech or Moderna if they have completed primary series vaccination but have not previously received a COVID-19 booster, and if they cannot or will not receive mRNA vaccines, according to Novavax. The 0.5 mL booster dose may be administered at least six months after completion of the primary vaccination with an authorized or approved COVID-19 vaccine, according to FDA.

"The U.S. now has access to the Novavax COVID-19 Vaccine, Adjuvanted, the first protein-based option, as a booster," Novavax President and CEO Stanley C. Erck said in a news release. "According to CDC data, almost 50 percent of adults who received their primary series have yet to receive their first booster dose. Offering another vaccine choice may help increase COVID-19 booster vaccination rates for these adults."

Related Videos